Critical Analysis: Iterum Therapeutics (NASDAQ:ITRM) and Sol-Gel Technologies (NASDAQ:SLGL)

Sol-Gel Technologies (NASDAQ:SLGL) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Valuation & Earnings

This table compares Sol-Gel Technologies and Iterum Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39 million	11.71	-$6.13 million	($5.64)	-12.31
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04

Sol-Gel Technologies has higher revenue and earnings than Iterum Therapeutics. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sol-Gel Technologies and Iterum Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-910.14%	-44.05%	-36.96%
Iterum Therapeutics	N/A	N/A	-65.54%

Analyst Ratings

This is a summary of recent recommendations for Sol-Gel Technologies and Iterum Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1	0	4	2	3.00
Iterum Therapeutics	1	2	0	0	1.67

Sol-Gel Technologies currently has a consensus target price of $197.50, suggesting a potential upside of 184.38%. Given Sol-Gel Technologies’ stronger consensus rating and higher probable upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than Iterum Therapeutics.

Institutional and Insider Ownership

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 2.0% of Iterum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Sol-Gel Technologies has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500.

Summary

Sol-Gel Technologies beats Iterum Therapeutics on 10 of the 15 factors compared between the two stocks.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.